EGFR and hepatocellular carcinoma: Combining lenvatinib with elacridar, a dual inhibitor of MDR1 and BCRP, or gefitinib, an EGFR inhibitor, may improve drug sensitivity in lenvatinib-resistant HCC and represent a viable therapeutic strategy.